Phoenix Financial Ltd. Trims Stake in Sol-Gel Technologies Ltd. $SLGL

Phoenix Financial Ltd. lessened its position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) by 80.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 494,040 shares of the company’s stock after selling 1,976,152 shares during the quarter. Phoenix Financial Ltd. owned 0.18% of Sol-Gel Technologies worth $3,656,000 as of its most recent filing with the Securities & Exchange Commission.

Sol-Gel Technologies Stock Performance

Shares of SLGL opened at $40.14 on Wednesday. The stock has a market capitalization of $111.82 million, a P/E ratio of -32.63 and a beta of 1.29. Sol-Gel Technologies Ltd. has a 1 year low of $4.01 and a 1 year high of $52.26. The company’s fifty day moving average is $28.34 and its two-hundred day moving average is $15.07.

Sol-Gel Technologies (NASDAQ:SLGL) last released its earnings results on Friday, August 15th. The company reported $4.17 EPS for the quarter, topping the consensus estimate of ($0.67) by $4.84. Sol-Gel Technologies had a negative net margin of 14.25% and a negative return on equity of 11.80%. The company had revenue of $17.26 million during the quarter, compared to analysts’ expectations of $2.86 million. Sell-side analysts predict that Sol-Gel Technologies Ltd. will post -0.28 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Sol-Gel Technologies in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Sol-Gel Technologies to a “buy” rating in a research note on Saturday, September 13th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.